ETOPOSIDE
Ovarian Diseases
Fujian Cancer HospitalSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
7 Active assets in the Ovarian Diseases cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Fujian Cancer Hospital | Phase 3 | BB |
(+)-VINCRISTINE Xiaoxiang Chen | Phase 3 | BB |
DEXAMETHASONE Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 2 | B |
Trabectedin Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 2 | B |
Temsirolimus AGO Study Group | Phase 2 | B |
View all 13 →
Same molecule, other indications
ETOPOSIDE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →